-+ 0.00%
-+ 0.00%
-+ 0.00%

Lakefront Biotherapeutics names Eric Hedrick chief medical officer

PUBT·06/08/2026 20:01:23
Listen to the news
Lakefront Biotherapeutics names Eric Hedrick chief medical officer
  • Lakefront appointed Eric Hedrick as chief medical officer, expanding leadership following the June 4 acquisition of Ouro Medicines operational assets.
  • Hedrick reports to CEO Henry Gosebruch, joining the management committee as the company shifts its R&D focus to the Ouro portfolio.
  • He joined Lakefront in July 2025 as clinical evaluation lead for new pipeline opportunities.
  • Hedrick previously served as chief executive physician at EQRx, interim chief medical officer at BeiGene, chief medical officer at Epizyme.
  • His earlier roles include interim chief medical officer at Pharmacyclics; he started at Genentech; trained at Memorial Sloan-Kettering Cancer Center.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakefront Biotherapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606081601PRIMZONEFULLFEED1001186569) on June 08, 2026, and is solely responsible for the information contained therein.